CFTR Modulators Reduce 8-Year Mortality Risk by 7.2% in Cystic Fibrosis

Shifting the Clinical Horizon in Cystic Fibrosis Management

The management of cystic fibrosis has transitioned toward targeting the underlying cystic fibrosis transmembrane conductance regulator (CFTR) protein defect rather than managing secondary complications alone [1, 2]. Current triple-combination therapies, such as the elexacaftor, tezacaftor, and ivacaftor regimen, have demonstrated the ability to improve forced expiratory volume in one second (FEV1) and nutritional status in clinical trials [3, 4]. However, approximately 10% to 15% of the patient population remains ineligible for these therapies due to specific genotypes or medication intolerance [5, 6]. Even among treated individuals, persistent microbial colonization and chronic inflammation can contribute to progressive pulmonary damage [7, 8]. While these short-term physiological improvements are well-documented, clinicians have lacked longitudinal evidence to determine if these therapies significantly extend life expectancy. To bridge this evidence gap, a large-scale registry analysis now provides a comprehensive look at long-term survival outcomes associated with initiating these medications.

A Decade of Registry Data on Survival Outcomes

To determine the real-world effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on survival, researchers conducted a retrospective cohort study analyzing a decade of data from the United States Cystic Fibrosis Foundation Patient Registry. The study period, spanning from 2012 to 2022, allowed for a robust assessment of long-term outcomes. The objective was to quantify the population-level treatment effect of initiating any CFTR modulator therapy compared to no initiation on the risk of death, shifting the focus from surrogate endpoints to a hard clinical outcome. The analysis included a total of 25,103 individuals across 178,835 clinical visits, providing substantial statistical power. Within this large cohort, 18,056 individuals initiated CFTR modulator therapy during the follow-up period. This extensive dataset enabled the authors to model the real-world impact of treatment initiation on mortality, offering a clear view of the life-extending potential of these therapies outside the controlled environment of a clinical trial.

Methodological Rigor in Assessing Treatment Initiation

To ensure the findings reflected current clinical standards, the researchers established inclusion criteria based on the specific age and genotype requirements of 2020 regulatory approvals for CFTR modulator prescriptions. All participants were required to have no prior use of these modulators, establishing a clean baseline for observing the effects of treatment initiation. The study design featured a dynamic assessment model where eligibility and treatment status were re-evaluated at every clinic or telehealth visit. This approach allowed individuals to contribute data at multiple time points, maximizing the utility of the longitudinal information from the 178,835 recorded encounters. Individuals were followed from each visit until death, lung transplantation, loss to follow-up, or the end of the study period. To maintain the integrity of the comparison, observations from untreated individuals were censored (removed from the untreated analysis) if they later initiated CFTR modulator therapy, preventing patient crossover from confounding the results. The researchers estimated 8-year survival probabilities using Kaplan-Meier analysis, a standard statistical method for measuring the fraction of subjects living for a certain amount of time after treatment. To identify factors associated with survival, they used Cox regression models. To address potential biases inherent in observational data, where treatment is not randomized, the authors applied inverse probability weighting. This statistical technique balances baseline covariates between the treated and untreated groups, creating a more reliable comparison by accounting for factors that might influence a patient's likelihood of starting therapy or being lost to follow-up.

Quantifying the Reduction in Mortality Risk

The longitudinal analysis provides a clear quantification of the survival advantage associated with initiating CFTR modulator therapy. The study's primary finding was that the 8-year absolute risk difference of death was -7.2% (95% CI: -9.6, -4.9) for those who started treatment compared to those who did not. This absolute risk reduction indicates that for every 14 patients who initiate modulator therapy, one death is prevented over an eight-year period. These findings establish that CFTR modulator therapies substantially reduce the risk of death among people with cystic fibrosis over a significant time frame, offering a more definitive outlook on long-term survival than was previously available. When evaluating the relative risk of mortality, the impact of treatment initiation was equally significant. The analysis found that the hazard for death was 66% lower after CFTR modulator initiation than without use. This reduction in the instantaneous risk of death is reflected in a hazard ratio of 0.34 (95% CI: 0.28, 0.41). For the practicing clinician, this means that at any given point in time, a patient on modulator therapy has approximately one-third the risk of dying compared to an eligible patient not on therapy. These data points serve as a critical tool for patient counseling and clinical planning.

Clinical Implications for Long-Term Care Planning

The demonstration that CFTR modulator therapies reduce the 8-year risk of death fundamentally alters the prognostic framework for cystic fibrosis. With an 8-year absolute risk difference of -7.2% and a hazard ratio for death of 0.34, physicians can now move beyond discussing short-term outcomes to counseling patients on long-term survival with greater precision. These findings allow clinical providers to set more accurate survival expectations, shifting the conversation from managing a life-limiting illness of childhood to planning for a chronic condition that extends well into adulthood. This requires clinicians to integrate these specific survival data, including the 66% reduction in the hazard of death, into shared decision-making with patients and their families. As the cystic fibrosis population experiences this documented increase in life expectancy, the healthcare system must adapt. The study's authors note that these results should prompt an appropriate allocation of care and resources aligned with this new reality. This involves transitioning from a model focused primarily on acute pulmonary interventions to one that proactively addresses the comorbidities of an aging population, such as cystic fibrosis-related diabetes, bone density loss, and renal dysfunction. Ensuring that clinical resources and multidisciplinary teams are equipped for this long-term, adult-focused care is essential for maintaining the quality of life that these therapeutic advancements have made possible.

References

1. Dawood SN, Rabih AM, Niaj A, et al. Newly Discovered Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review.. Cureus. 2022. doi:10.7759/cureus.29359

2. Ren CL, Morgan RL, Oermann C, et al. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.. Annals of the American Thoracic Society. 2018. doi:10.1513/AnnalsATS.201707-539OT

3. Li Q, Liu S, Ma X, Yu J. Effectiveness and Safety of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Children With Cystic Fibrosis: A Meta-Analysis.. Frontiers in pediatrics. 2022. doi:10.3389/fped.2022.937250

4. Middleton PG, Mall M, Dřevı́nek P, et al. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New England Journal of Medicine. 2019. doi:10.1056/nejmoa1908639

5. Davies JC, Polineni D, Boyd A, et al. Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial. American Journal of Respiratory and Critical Care Medicine. 2024. doi:10.1164/rccm.202402-0389CI

6. Mayer-Hamblett N, Kerper NR, Clancy JP, et al. Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials.. The Lancet Respiratory Medicine. 2025. doi:10.1016/S2213-2600(25)00206-1

7. Knoll RL, Brauny MM, Robert E, et al. CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial.. Nature communications. 2025. doi:10.1038/s41467-025-64218-z

8. Elborn J, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe S. EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics.. Contemporary Clinical Trials. 2018. doi:10.1016/j.cct.2018.07.014